Clinical Trials Browser

Phase 2 × INDUSTRY × lenvatinib × Clear all

NCT07081633 2026-05-12

TREMENDOUS-2

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05903833 2026-05-11

PIERCE

Phase 2 Recruiting

Vulvar Neoplasms

NCT03797326 2026-05-04

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07219459 2026-04-27

GDFATHERHCC01

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05775159 2026-04-17

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06036836 2026-03-19

MK-4280A-010

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Phase 2 Not yet recruiting

Advanced Endometrial Cancer

NCT04428151 2025-12-04

LEAP-009

Phase 2 Completed

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04704219 2025-12-03

KEYNOTE-B61

Phase 2 Completed

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Phase 2 Recruiting

Kidney Neoplasms

NCT04447755 2025-10-03

E7080-G000-231

Phase 2 Completed

127 enrolled 29 charts

Recurrence

NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

Phase 2 Completed

58 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT03516981 2025-07-01

MK-3475-495

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06984718 2025-05-22

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04976634 2025-04-06

MK-6482-016

Phase 2 Active not recruiting

Neoplasms

NCT03173560 2025-04-01

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Phase 2 Completed

343 enrolled 25 charts

Carcinoma, Renal Cell

NCT04401800 2025-03-10

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Phase 2 Completed

64 enrolled 23 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05195294 2025-03-10

Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC

Phase 2 Not yet recruiting

Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular

NCT03477175 2025-01-07

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Phase 2 Completed

40 enrolled 13 charts

Other solid neoplasm

Solid Tumors

NCT04154189 2024-07-22

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Phase 2 Completed

81 enrolled 22 charts

Recurrence, Osteosarcoma

NCT01111461 2023-06-22

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Phase 2 Completed

133 enrolled 16 charts

Endometrial Neoplasms

NCT02915783 2023-01-17

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Phase 2 Completed

41 enrolled 11 charts

Neoplasm Metastasis

NCT01137604 2022-09-29

A Study in Subjects With Recurrent Malignant Glioma

Phase 2 Completed

151 enrolled 17 charts

Glioma

NCT02702388 2021-11-24

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Phase 2 Completed

241 enrolled 32 charts

Thyroid Neoplasms

NCT04741165 2021-02-05

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT02579616 2020-12-23

Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy

Phase 2 Completed

29 enrolled 16 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT01728623 2020-08-14

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Phase 2 Completed

51 enrolled 15 charts

Thyroid Neoplasms

NCT00784303 2020-04-22

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Phase 2 Completed

117 enrolled 19 charts

Thyroid Neoplasms

NCT03433703 2019-12-06

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Phase 2 Terminated

8 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01136967 2019-11-13

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Phase 2 Completed

182 enrolled 63 charts

Melanoma

NCT02657369 2019-10-15

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Phase 2 Terminated

34 enrolled 13 charts

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT01877083 2019-08-13

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

Phase 2 Completed

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01529112 2017-09-26

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Phase 2 Completed

135 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung